NASDAQ:ATOS - Atossa Genetics Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $1.50 -0.09 (-5.66 %) (As of 10/19/2018 04:00 PM ET)Previous Close$1.50Today's Range$1.48 - $1.599052-Week Range$1.41 - $19.08Volume88,815 shsAverage Volume220,786 shsMarket Capitalization$8.06 millionP/E RatioN/ADividend YieldN/ABeta3.37 Company ProfileDiscussionAnalyst RatingsChartEarnings HistoryFinancialsInsider TradesHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Atossa Genetics Inc. a clinical-stage pharmaceutical company, focuses on the development and sale of novel therapeutics and delivery methods for the treatment of breast cancer and other breast conditions in the United States. The company is conducting a Phase 2 clinical study using microcatheters to deliver fulvestrant as a potential treatment of ductal carcinoma in situ and breast cancer; and a pharmaceutical program under development is Endoxifen, an active metabolite of tamoxifen, as well as treatment for breast density and other breast health conditions. It offers ForeCYTE Breast Aspirator and FullCYTE Breast Aspirator, which collects specimens of nipple aspirate fluid (NAF)for cytological testing at a laboratory; and a transport kit to assist with the packaging and transport of NAF samples to a laboratory, as well as manufactures and sells various medical devices primarily consisting of tools to assist breast surgeons. Atossa Genetics Inc. was founded in 2009 and is headquartered in Seattle, Washington. Receive ATOS News and Ratings via Email Sign-up to receive the latest news and ratings for ATOS and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Surgical & medical instruments Sub-IndustryN/A SectorMedical SymbolNASDAQ:ATOS CUSIPN/A Webwww.atossagenetics.com Phone206-325-6086 Debt Debt-to-Equity RatioN/A Current Ratio5.45 Quick Ratio5.45 Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / CashN/A Book Value$2.61 per share Price / Book0.57 Profitability EPS (Most Recent Fiscal Year)N/A Net Income$-8,120,000.00 Net MarginsN/A Return on Equity-142.39% Return on Assets-117.34% Miscellaneous Employees7 Outstanding Shares5,070,000Market Cap$8.06 million Atossa Genetics (NASDAQ:ATOS) Frequently Asked Questions What is Atossa Genetics' stock symbol? Atossa Genetics trades on the NASDAQ under the ticker symbol "ATOS." When did Atossa Genetics' stock split? How did Atossa Genetics' stock split work? Shares of Atossa Genetics reverse split on Friday, April 20th 2018. The 1-12 reverse split was announced on Friday, April 20th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, April 19th 2018. An investor that had 100 shares of Atossa Genetics stock prior to the reverse split would have 8 shares after the split. How were Atossa Genetics' earnings last quarter? Atossa Genetics Inc (NASDAQ:ATOS) posted its earnings results on Monday, August, 13th. The company reported ($2.90) EPS for the quarter, missing analysts' consensus estimates of ($0.37) by $2.53. View Atossa Genetics' Earnings History. When is Atossa Genetics' next earnings date? Atossa Genetics is scheduled to release their next quarterly earnings announcement on Tuesday, November 13th 2018. View Earnings Estimates for Atossa Genetics. What price target have analysts set for ATOS? 2 Wall Street analysts have issued 1 year price objectives for Atossa Genetics' stock. Their predictions range from $7.00 to $10.00. On average, they expect Atossa Genetics' stock price to reach $8.50 in the next twelve months. This suggests a possible upside of 466.7% from the stock's current price. View Analyst Price Targets for Atossa Genetics. What is the consensus analysts' recommendation for Atossa Genetics? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Atossa Genetics in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Atossa Genetics. Who are some of Atossa Genetics' key competitors? Some companies that are related to Atossa Genetics include PAVmed (PAVM), Valeritas (VLRX), Titan Medical (TMDI), CELLECT BIOTECH/S (APOP), SANUWAVE Health (SNWV), Hancock Jaffe Laboratories (HJLI), Presbia (LENS), Dynatronics (DYNT), DarioHealth (DRIO), Biostage (BSTG), Invivo Therapeutics (NVIV), Cytocore (MDIT), Avinger (AVGR), Alliqua Biomedical (ALQA) and Neurometrix (NURO). Who are Atossa Genetics' key executives? Atossa Genetics' management team includes the folowing people: Dr. Steven C. Quay, Chairman, CEO & Pres (Age 67)Mr. Kyle Guse CPA, Esq., CPA, CFO, Gen. Counsel & Sec. (Age 54)Ms. Janet Rose Rea, Sr. VP of Regulatory, Quality & Clinical AffairsMr. Pieter Van Der Poel, VP of European Commercial Operations (Age 55)Dr. Jack Cuzick, Member of Scientific Advisory Board How do I buy shares of Atossa Genetics? Shares of ATOS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Atossa Genetics' stock price today? One share of ATOS stock can currently be purchased for approximately $1.50. How big of a company is Atossa Genetics? Atossa Genetics has a market capitalization of $8.06 million. Atossa Genetics employs 7 workers across the globe. What is Atossa Genetics' official website? The official website for Atossa Genetics is http://www.atossagenetics.com. How can I contact Atossa Genetics? Atossa Genetics' mailing address is 107 SPRING STREET, SEATTLE WA, 98104. The company can be reached via phone at 206-325-6086 or via email at [email protected] MarketBeat Community Rating for Atossa Genetics (NASDAQ ATOS)Community Ranking: 2.3 out of 5 ( )Outperform Votes: 104 (Vote Outperform)Underperform Votes: 121 (Vote Underperform)Total Votes: 225MarketBeat's community ratings are surveys of what our community members think about Atossa Genetics and other stocks. Vote "Outperform" if you believe ATOS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ATOS will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 10/20/2018 by MarketBeat.com StaffFeatured Article: What are CEFs?